To support the introduction of a change in Burkina Faso’s infant pneumococcal vaccine schedule to include a booster dose and to evaluate the impact of the country’s capacity to control pneumococcal disease among children and adults.

To assess the acceptability, safety, feasibility and cost of a Typhoid Conjugate Vaccine (TCV) delivered as part of a ministry-led campaign in Harare, Zimbabwe. This evaluation will provide lessons learned and recommendations for future use of TCV in outbreak settings, and to inform typhoid control strategies.

To conduct targeted assessments involving vaccine research and surveillance. The current studies range from a meningitis carriage study in Burkina Faso to measure the impact of the MenA vaccine, to rotavirus surveillance in Mozambique to look at vaccine effectiveness.

To explore the feasibility of human papillomavirus vaccine impact in a low resource setting.

To help CDC contribute to research about genetic changes in pneumococcal bacteria that impact the effectiveness of vaccination in developing countries. CDC will provide isolates from their Global Pneumococcal Strain Bank, sequence isolates from the Active Bacterial Core surveillance collaboration, and provide expert guidance on analysis and interpretation of the data.